Ultra-pure agonists of guanylate cyclase C, method of making and using same
US-10745441-B2 · Aug 18, 2020 · US
Ultra-pure agonists of guanylate cyclase C, method of making and using same
US11142549B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11142549-B2 |
| Application number | US-202016921450-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 6, 2020 |
| Priority date | Jun 5, 2013 |
| Publication date | Oct 12, 2021 |
| Grant date | Oct 12, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
First claim
Opening claim text (preview).
We claim: 1. An oral formulation comprising: (a) a purified peptide comprising the Guanylate Cyclase-C(GCC) agonist of amino acid sequence of SEQ ID NO: 1, wherein the purified peptide comprises less than 0.05% trifluoroacetic acid (TFA) by weight of the purified peptide; and (b) one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients comprises microcrystalline cellulose. 2. The oral formulation of claim 1 , comprising 0.01 mg to 10 mg of the purified peptide. 3. The oral formulation of claim 2 , comprising 0.1 mg to 5 mg of the purified peptide. 4. The oral formulation of claim 3 , comprising 3 mg of the purified peptide. 5. The oral formulation of claim 1 , wherein the purified peptide has an average particle size of 80-120 μm. 6. The oral formulation of claim 1 , wherein the one or more pharmaceutically acceptable excipients further comprises magnesium stearate.
Assignees
Inventors
Classifications
Elution mode · CPC title
Extraction; Separation; Purification · CPC title
Guanylate cyclase (4.6.1.2) · CPC title
Lyases (4.) · CPC title
Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11142549B2 cover?
- The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
- Who is the assignee on this patent?
- Bausch Health Ireland Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).